Showing results (1-10 of 279) with videos related to
Sort By:
Pageof 28
Antimicrobial Agents and Chemotherapy|June 26, 2013
In Vivo Effects of Cefazolin, Daptomycin, and Nafcillin in Experimental Endocarditis with a Methicillin-Susceptible Staphylococcus aureus Strain Showing an Inoculum Effect against CefazolinEsteban C Nannini, Kavindra V Singh, Cesar A Arias, et al.Antimicrobial Agents and Chemotherapy|May 10, 2017
Efficacy of Ceftaroline against Methicillin-Susceptible Staphylococcus aureus Exhibiting the Cefazolin High-Inoculum Effect in a Rat Model of EndocarditisKavindra V Singh, Truc T Tran, Esteban C Nannini, et al.Current Gastroenterology Reports|September 14, 2002
HIV1 and the gut in the era of highly active antiretroviral therapyEsteban C Nannini, Pablo C OkhuysenExpert Opinion on Pharmacotherapy|August 2, 2008
A new lipoglycopeptide: telavancinEsteban C Nannini, Martin E StryjewskiThe Journal of Infectious Diseases|May 26, 2026
The Maxwell Finland Lecture 2025: Antimicrobial Resistance At The Bedside: Translating Science Into Patient OutcomesCesar A AriasThe Journal of Infectious Diseases|January 6, 2005
Importance of gls24 in virulence and stress response of Enterococcus faecalis and use of the Gls24 protein as a possible immunotherapy targetFang Teng, Esteban C Nannini, Barbara E MurrayThe Journal of Antimicrobial Chemotherapy|June 25, 2013
Cefazolin high-inoculum effect in methicillin-susceptible Staphylococcus aureus from South American hospitalsSandra Rincón, Jinnethe Reyes, Lina Paola Carvajal, et al.Expert Opinion on Pharmacotherapy|April 21, 2010
Ceftaroline for complicated skin and skin-structure infectionsEsteban C Nannini, Martin E Stryjewski, G Ralph CoreyClinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 15, 2003
Relapse of type A beta-lactamase-producing Staphylococcus aureus native valve endocarditis during cefazolin therapy: revisiting the issueEsteban C Nannini, Kavindra V Singh, Barbara E MurrayExpert Review of Anti-Infective Therapy|October 4, 2012
Telavancin for the treatment of hospital-acquired pneumonia: findings from the ATTAIN studiesEsteban C Nannini, G Ralph Corey, Martin E StryjewskiPageof 28